Literature DB >> 18502302

Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study.

Valma Harjutsalo1, Lena Sjöberg, Jaakko Tuomilehto.   

Abstract

BACKGROUND: Finland has the highest incidence of type 1 diabetes worldwide, reaching 40 per 100,000 people per year in the 1990s. Our aim was to assess the temporal trend in type 1 diabetes incidence since 2000 in Finnish children aged younger than 15 years and to predict the number of cases of type 1 diabetes in the future.
METHODS: Children with newly diagnosed type 1 diabetes in Finland who were listed on the National Public Health Institute diabetes register, Central Drug Register, and Hospital Discharge Register in 1980-2005 were included in a cohort study. We excluded patients with type 2 diabetes and diabetes occurring secondary to other conditions, such as steroid use, Down's syndrome, and congenital malformations of pancreas.
FINDINGS: 10,737 children-5816 boys and 4921 girls-were diagnosed with type 1 diabetes before 15 years of age during 1980-2005. The average age-standardised incidence was 42.9 per 100,000 per year (95% CI 42.6-44.3) during this period, increasing from 31.4 per 100,000 per year in 1980 to 64.2 per 100,000 per year in 2005. The age-specific rates per 100,000 per year were 31.0, 50.5, and 50.6 at ages 0-4 years, 5-9 years, and 10-14-years, respectively. We noted a significant non-linear component to the time trend (p<0.0003). In children aged 0-4 years, the increase was largest, at 4.7% more affected every year. The overall boy-to-girl ratio of incidence was 1.1; at the age of 13 years, it was 1.7 (1.4-2.0). The predicted cumulative number of new cases with type 1 diabetes before 15 years of age between 2006 and 2020 was about 10 800.
INTERPRETATION: The incidence of type 1 diabetes in Finnish children is increasing even faster than before. The number of new cases diagnosed at or before 14 years of age will double in the next 15 years and the age of onset will be younger (0-4 years).

Entities:  

Mesh:

Year:  2008        PMID: 18502302     DOI: 10.1016/S0140-6736(08)60765-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  204 in total

1.  Environmental factors and primary prevention in type 1 diabetes.

Authors:  Jorma Ilonen; Outi Vaarala; Hans K Akerblom; Mikael Knip
Journal:  Pediatr Endocrinol Diabetes Metab       Date:  2009

2.  Descriptive epidemiology of type 1 diabetes--is it still in?

Authors:  M Knip
Journal:  Diabetologia       Date:  2012-03-09       Impact factor: 10.122

3.  Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase.

Authors:  C C Patterson; E Gyürüs; J Rosenbauer; O Cinek; A Neu; E Schober; R C Parslow; G Joner; J Svensson; C Castell; P J Bingley; E Schoenle; P Jarosz-Chobot; B Urbonaité; U Rothe; C Krzisnik; C Ionescu-Tirgoviste; I Weets; M Kocova; G Stipancic; M Samardzic; C E de Beaufort; A Green; G G Dahlquist; G Soltész
Journal:  Diabetologia       Date:  2012-05-26       Impact factor: 10.122

Review 4.  The 'hygiene hypothesis' for autoimmune and allergic diseases: an update.

Authors:  H Okada; C Kuhn; H Feillet; J-F Bach
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

Review 5.  Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Authors:  Jeffrey A Bluestone; Kevan Herold; George Eisenbarth
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

6.  Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology.

Authors:  Ken T Coppieters; Bart O Roep; Matthias G von Herrath
Journal:  Semin Immunopathol       Date:  2010-12-18       Impact factor: 9.623

7.  Serum 25-hydroxyvitamin D level during early pregnancy and type 1 diabetes risk in the offspring.

Authors:  M E Miettinen; L Reinert; L Kinnunen; V Harjutsalo; P Koskela; H-M Surcel; C Lamberg-Allardt; J Tuomilehto
Journal:  Diabetologia       Date:  2012-01-20       Impact factor: 10.122

8.  Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes.

Authors:  Jan Czyzyk; Octavian Henegariu; Paula Preston-Hurlburt; Raman Baldzizhar; Christine Fedorchuk; Enric Esplugues; Kim Bottomly; Frans K Gorus; Kevan Herold; Richard A Flavell
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

9.  What can we learn from inflammatory bowel disease in developing countries?

Authors:  Sunny H Wong; Siew C Ng
Journal:  Curr Gastroenterol Rep       Date:  2013-03

Review 10.  Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease.

Authors:  Juha Grönholm; Michael J Lenardo
Journal:  Clin Immunol       Date:  2014-12-05       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.